Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Agranulocytosis D000380 7 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amnesia D000647 12 associated lipids
Anaphylaxis D000707 35 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Angina Pectoris D000787 27 associated lipids
Angina, Unstable D000789 14 associated lipids
Hypoxia D000860 23 associated lipids
Anthrax D000881 1 associated lipids
Arenaviridae Infections D001117 1 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthus Reaction D001183 8 associated lipids
Ascites D001201 25 associated lipids
Asphyxia Neonatorum D001238 4 associated lipids
Asthma D001249 52 associated lipids
Pulmonary Atelectasis D001261 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Birth Weight D001724 23 associated lipids
Blister D001768 16 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Body Weight D001835 333 associated lipids
Bovine Virus Diarrhea-Mucosal Disease D001912 2 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Brain Injuries D001930 4 associated lipids
Bronchial Diseases D001982 3 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchopulmonary Dysplasia D001997 4 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Burns D002056 34 associated lipids
Burns, Inhalation D002059 4 associated lipids
Carbon Monoxide Poisoning D002249 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Central Nervous System Diseases D002493 10 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cholecystitis D002764 8 associated lipids
Cholestasis D002779 23 associated lipids
Cholestasis, Intrahepatic D002780 4 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Cluster Headache D003027 4 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Colonic Diseases D003108 5 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Conjunctivitis D003231 7 associated lipids
Constriction, Pathologic D003251 8 associated lipids
Contracture D003286 3 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Coronary Thrombosis D003328 7 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Death, Sudden D003645 12 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Dictyocaulus Infections D004022 1 associated lipids
Disseminated Intravascular Coagulation D004211 7 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyslexia D004410 3 associated lipids
Ear Diseases D004427 7 associated lipids
Edema D004487 152 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Epilepsy D004827 35 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Extravasation of Diagnostic and Therapeutic Materials D005119 3 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Gastritis D005756 27 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Glioma D005910 112 associated lipids
Gliosis D005911 6 associated lipids
Glomerulonephritis D005921 35 associated lipids
Glomerulonephritis, IGA D005922 7 associated lipids
Rhinitis, Allergic, Seasonal D006255 7 associated lipids
Heart Arrest D006323 13 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Cardiomegaly D006332 31 associated lipids
Heart Injuries D006335 6 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Hemolysis D006461 131 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Pritchard PH The degradation of platelet-activating factor by high-density lipoprotein in rat plasma. Effect of ethynyloestradiol administration. 1987 Biochem. J. pmid:3689334
Hill CE and Olson MS Stimulation of uric acid release from the perfused rat liver by platelet activating factor or potassium. 1987 Biochem. J. pmid:3689345
Ramesha CS and Pickett WC Human neutrophil platelet-activating factor: molecular heterogeneity in unstimulated and ionophore-stimulated cells. 1987 Biochim. Biophys. Acta pmid:3113489
Bolin RW et al. Lung endothelial and epithelial permeability after platelet-activating factor. 1987 J. Appl. Physiol. pmid:3693212
Smallbone BW et al. Effects of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep. 1987 J. Pharmacol. Exp. Ther. pmid:2821222
Robertson DA et al. Negative inotropic effect of platelet-activating factor on human myocardium: a pharmacological study. 1987 J. Pharmacol. Exp. Ther. pmid:3694533
Nomura H Biological action and structural specificity of diacylglycerol in platelet activation. 1987 Kobe J Med Sci pmid:3695296
Hébert RL et al. Hemodynamic effects of PAF-acether on the dog kidney. 1987 Prostaglandins Leukot Med pmid:3033688
Tysnes OB et al. Neomycin inhibits agonist-stimulated polyphosphoinositide metabolism and responses in human platelets. 1987 Biochem. Biophys. Res. Commun. pmid:3034251
Barnes PJ et al. The effect of platelet activating factor on pulmonary beta-adrenoceptors. 1987 Br. J. Pharmacol. pmid:3034367
Gordeev KIu et al. [Synthesis of 1-(1-alkenyl)-2-acetyl-sn-glycero-3-phosphocholines, the aldehyded analogs of platelet activating factor]. 1987 Bioorg. Khim. pmid:3566815
Davenas E et al. Effect of mouse peritoneal macrophages of orally administered very high dilutions of silica. 1987 Eur. J. Pharmacol. pmid:3034632
Stahl GL and Lefer AM Heterogeneity of vascular smooth muscle responsiveness to lipid vasoactive mediators. 1987 Blood Vessels pmid:3567363
Sigal CE et al. Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC). 1987 J. Clin. Immunol. pmid:3571436
Godfroid JJ et al. Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity. 1987 J. Med. Chem. pmid:3572968
Simon MF et al. Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets. 1987 Thromb. Res. pmid:3576518
Alam I and Silver MJ Metabolism of 1-alkyl-2-acyl-GPC in human platelets in response to stimulation by thrombin. 1987 Thromb. Res. pmid:3576519
Kusner EJ et al. Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat. 1987 Agents Actions pmid:3577957
Kawasaki T and Snyder F The metabolism of lyso-platelet-activating factor (1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine) by a calcium-dependent lysophospholipase D in rabbit kidney medulla. 1987 Biochim. Biophys. Acta pmid:3036238
Camussi G et al. Receptor antagonist of platelet activating factor inhibits inflammatory injury induced by in situ formation of immune complexes in renal glomeruli and in the skin. 1987 J. Lab. Clin. Med. pmid:2955066
Shukla SD et al. Activation of phospholipase C in platelets by platelet activating factor and thrombin causes hydrolysis of a common pool of phosphatidylinositol 4,5-bisphosphate. 1987 Biochim. Biophys. Acta pmid:3036249
Grignani G and Jamieson GA Tissue factor-dependent activation of platelets by cells and microvesicles of SK-OS-10 human osteogenic sarcoma cell line. 1987 Invasion Metastasis pmid:3036740
Foegh ML et al. Leukotrienes, thromboxane, and platelet activating factor in organ transplantation. 1987 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:2959038
Robertson DN and Smith GM Role of thromboxane A2, 5-hydroxytryptamine, and platelet activating factor in collagen-induced sudden death in rabbits. 1987 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:2959049
d'Humieres S et al. Platelet activating factor acether is involved in thrombin-induced synthesis of prostacyclin by human endothelial cells. 1987 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:2959051
Whittle BJ et al. Gastric vascular and mucosal damaging actions of platelet activating factor in the canine stomach. 1987 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:2959063
Handley DA et al. Inhibition by SRI 63-072 and SRI 63-119 of PAF-acether and immune complex effects in the guinea pig. 1987 Eur. J. Pharmacol. pmid:2959489
Martin TR et al. Relative contribution of leukotriene B4 to the neutrophil chemotactic activity produced by the resident human alveolar macrophage. 1987 J. Clin. Invest. pmid:2821074
Woodard DS et al. The final step in the de novo biosynthesis of platelet-activating factor. Properties of a unique CDP-choline:1-alkyl-2-acetyl-sn-glycerol choline-phosphotransferase in microsomes from the renal inner medulla of rats. 1987 J. Biol. Chem. pmid:3029085
Chang SW et al. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. 1987 J. Clin. Invest. pmid:3553241
Saunders RN and Handley DA Platelet-activating factor antagonists. 1987 Annu. Rev. Pharmacol. Toxicol. pmid:3555317
Stafforini DM et al. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. 1987 J. Biol. Chem. pmid:3558407
Adamson LM et al. Mechanistic studies of early pregnancy associated thrombocytopenia (EPAT) in the mouse. 1987 Am J Reprod Immunol Microbiol pmid:3605486
Fujita K et al. Synthesis and biological activity of fluorine-modified platelet activating factors. 1987 Chem. Pharm. Bull. pmid:3594676
O'Neill C et al. Use of a bioassay for embryo-derived platelet-activating factor as a means of assessing quality and pregnancy potential of human embryos. 1987 Fertil. Steril. pmid:3595903
Etienne A et al. Inhibition of rat endotoxin-induced lethality by BN 52021 and BN 52063, compounds with PAF-acether antagonistic effect and protease-inhibitory activity. 1987 Int J Tissue React pmid:3596954
Doly M et al. Effects of PAF-acether on electrophysiological response of isolated retina. 1987 Int J Tissue React pmid:3596955
Casals-Stenzel J Effects of WEB 2086, a novel antagonist of platelet activating factor, in active and passive anaphylaxis. 1987 Immunopharmacology pmid:3597059
Handley DA et al. Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog. 1987 Immunopharmacology pmid:3597060
Ramesha CS and Pickett WC Fatty acid composition of diacyl, alkylacyl, and alkenylacyl phospholipids of control and arachidonate-depleted rat polymorphonuclear leukocytes. 1987 J. Lipid Res. pmid:3106551
Dallob A et al. Pharmacological evidence for a role of lipoxygenase products in platelet-activating factor (PAF)-induced hyperalgesia. 1987 Biochem. Pharmacol. pmid:2822047
Casals-Stenzel J et al. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. 1987 J. Pharmacol. Exp. Ther. pmid:3598913
Purdon AD et al. Ionophore-stimulated rat basophilic leukemia cells produce PAF-acether. 1987 Int. Arch. Allergy Appl. Immunol. pmid:3100454
Rola-Pleszczynski M et al. Inhibition of human lymphocyte proliferation and interleukin 2 production by platelet activating factor (PAF-acether): reversal by a specific antagonist, BN 52021. 1987 Biochem. Biophys. Res. Commun. pmid:3493773
Wilcox RW et al. The degradation of platelet-activating factor and related lipids: susceptibility to phospholipases C and D. 1987 Lipids pmid:3444369
Kudo I et al. Antitumor activity of synthetic alkylphospholipids with or without PAF activity. 1987 Lipids pmid:3444379
Söling U et al. Effect of synthetic phospholipids on platelet aggregation and serotonin release. 1987 Lipids pmid:3444380
Schick HD et al. Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro. 1987 Lipids pmid:3444383
Hirafuji M et al. Regulation of PAF-acether (platelet-activating factor) biosynthesis in cultured human vascular endothelial cells stimulated with thrombin. 1987 Biochim. Biophys. Acta pmid:2888488
Grigorian GY and Ryan US Platelet-activating factor effects on bovine pulmonary artery endothelial cells. 1987 Circ. Res. pmid:3040294
Brigham KL Conference summary: lipid mediators in the pulmonary circulation. 1987 Am. Rev. Respir. Dis. pmid:2820285
Lamant V et al. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba. 1987 Biochem. Pharmacol. pmid:2820421
Ramesha CS and Pickett WC Species-specific variations in the molecular heterogeneity of the platelet-activating factor. 1987 J. Immunol. pmid:3100641
Codde JP et al. Can the synthesis of platelet-activating factor, a potent vasodilator and pro-aggregatory agent, be altered by dietary marine oils? 1987 Clin. Exp. Pharmacol. Physiol. pmid:2822306
Makowka L et al. Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response. 1987 Ann. Surg. pmid:3310931
Hanahan DJ and Kumar R Platelet activating factor; chemical and biochemical characteristics. 1987 Prog. Lipid Res. pmid:3313430
Pignol B et al. Effect of platelet-activating factor (PAF-acether) and its specific receptor antagonist, BN 52021, on interleukin 1 (IL1) release and synthesis by rat spleen adherent monocytes. 1987 Prostaglandins pmid:3313526
Braquet P and Rola-Pleszczynski M The role of PAF in immunological responses: a review. 1987 Prostaglandins pmid:3313527
Braquet P and Bourgain RH Anti-anaphylactic properties of BN 52021: a potent platelet activating factor antagonist. 1987 Adv. Exp. Med. Biol. pmid:3314403
Barnes PJ New concepts in the pathogenesis of bronchial hyperresponsiveness. 1987 Agents Actions Suppl. pmid:3314413
Mustard JF et al. Platelet activation--an overview. 1987 Agents Actions Suppl. pmid:3314414
Di Marzo V et al. Platelet activating factor-mediated leukotriene biosynthesis in rat lungs: effect of prostaglandins E1 and F1 alpha. 1987 Biochem. Biophys. Res. Commun. pmid:2822041
Vargaftig BB and Braquet PG PAF-acether today--relevance for acute experimental anaphylaxis. 1987 Br. Med. Bull. pmid:2825900
Kochanek PM et al. Platelet activating factor receptor blockade enhances recovery after multifocal brain ischemia. 1987 Life Sci. pmid:2826947
Wang J and Dunn MJ Platelet-activating factor mediates endotoxin-induced acute renal insufficiency in rats. 1987 Am. J. Physiol. pmid:2827506
Panetta T et al. Effects of a platelet activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain: inhibition of ischemia-reperfusion induced cerebral injury. 1987 Biochem. Biophys. Res. Commun. pmid:2827647
O'Flaherty JT Phospholipid metabolism and stimulus-response coupling. 1987 Biochem. Pharmacol. pmid:3030324
Murphy WG et al. Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura. 1987 Br. J. Haematol. pmid:3499167
Suemune H et al. Asymmetric synthesis of (+)- and (-)-batyl alcohol, a key synthetic intermediate for platelet-activating factor, by using biocatalysts. 1987 Chem. Pharm. Bull. pmid:3427701
Shimazaki N et al. Diketopiperazine derivatives, a new series of platelet-activating factor inhibitors. 1987 Chem. Pharm. Bull. pmid:3427732
Lang CH et al. Attenuation of endotoxin-induced increase in glucose metabolism by platelet-activating factor antagonist. 1987 Circ. Shock pmid:3427772
Korth R and Benveniste J BN 52021 displaces [3H]paf-acether from, and inhibits its binding to intact human platelets. 1987 Eur. J. Pharmacol. pmid:3428349
Steiger J et al. Platelet activating factor (PAF) is a potent stimulator of porcine tracheal fluid secretion in vitro. 1987 Eur. J. Pharmacol. pmid:3428351
Karasawa K et al. Antibody to platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF). 1987 J. Biochem. pmid:3429442
Wymann MP et al. The onset of the respiratory burst in human neutrophils. Real-time studies of H2O2 formation reveal a rapid agonist-induced transduction process. 1987 J. Biol. Chem. pmid:3040727
Bull HA and Machin SJ The haemostatic function of the vascular endothelial cell. 1987 Blut pmid:3111566
Vane J and Botting R Inflammation and the mechanism of action of anti-inflammatory drugs. 1987 FASEB J. pmid:3111928
Riedel A and Mest HJ The effect of PAF (platelet-activating factor) on experimental cardiac arrhythmias and its inhibition by substances influencing arachidonic acid metabolites. 1987 Prostaglandins Leukot Med pmid:3112804
Shimokawa H et al. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. 1987 Circ. Res. pmid:3113760
Adnot S et al. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets. 1987 Agents Actions pmid:3115070
Montrucchio G et al. The pattern of cardiovascular alterations induced by infusion of platelet-activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition. 1987 Agents Actions pmid:3115072
Evans TW et al. Effect of platelet-activating factor on airway vascular permeability: possible mechanisms. 1987 J. Appl. Physiol. pmid:3115939
Livio M et al. A platelet-activating factor receptor antagonist protects against renal function deterioration in nephrotoxic nephritis. 1987 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:2823570
Stenzel H et al. Effect of the PAF-antagonist SRI 63-441 on the allergic reaction in awake dogs with natural asthma. 1987 Agents Actions Suppl. pmid:2823582
O'Flaherty JT and Wykle RL Metabolic origin and fate of platelet-activating factor. 1987 Agents Actions Suppl. pmid:2823583
Gomez-Cambronero J et al. The diacylglycerol kinase inhibitor R59022 potentiates superoxide production but not secretion induced by fMet-Leu-Phe: effects of leupeptin and the protein kinase C inhibitor H-7. 1987 Biochem. Biophys. Res. Commun. pmid:2823810
Bertani T et al. Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. 1987 Kidney Int. pmid:3039232
Abramovici Y et al. Control of the proliferation and differentiation of GEJ under platelet aggregating factor treatment. 1987 Acta Endocrinol Suppl (Copenh) pmid:3475908
Krishnamurthi S et al. Effect of phorbol 12-myristate 13-acetate (PMA) on agonist-induced arachidonate release and 5-hydroxytryptamine secretion in human platelets. Dependence of effects on agonist type and time of incubation with PMA. 1987 Biochim. Biophys. Acta pmid:3101746
Doebber TW and Wu MS Platelet-activating factor (PAF) stimulates the PAF-synthesizing enzyme acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine O2-acetyltransferase and PAF synthesis in neutrophils. 1987 Proc. Natl. Acad. Sci. U.S.A. pmid:3478712
PAF, platelets and asthma. Proceedings of a meeting. September 7-9, 1986. 1987 Agents Actions Suppl. pmid:3478993
Farr RS et al. Platelet abnormalities in asthma--do they exist in humans? 1987 Agents Actions Suppl. pmid:3478994
Menz G et al. Lack of PAF release in extrinsic asthma. 1987 Agents Actions Suppl. pmid:3478995
Benhamou M and Mencia-Huerta JM Effect of glucocorticosteroids on the expression of Fc epsilon R1 and on mediator release from mast cells. 1986 Sep-Oct Ann. Inst. Pasteur Immunol. pmid:2948525
Morley J Theophylline in asthma. 1986 Sep-Oct Bull Eur Physiopathol Respir pmid:3801711
von Tscharner V et al. Ion channels in human neutrophils activated by a rise in free cytosolic calcium concentration. 1986 Nov 27-Dec 3 Nature pmid:2431318
Kako KJ Membrane phospholipids and plasmalogens in the ischemic myocardium. 1986 May-Jun Can J Cardiol pmid:2424580
Rosam AC et al. Potent ulcerogenic actions of platelet-activating factor on the stomach. 1986 Jan 2-8 Nature pmid:3510396
Desquand S et al. Interference of BN 52021 (ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pig. 1986 Eur. J. Pharmacol. pmid:3019727
Daniel LW et al. A novel mechanism of diglyceride formation. 12-O-tetradecanoylphorbol-13-acetate stimulates the cyclic breakdown and resynthesis of phosphatidylcholine. 1986 J. Biol. Chem. pmid:3087989